Industry Update

FDA Expands Use of Real-World Evidence in Medical Device Applications

The U.S. Food and Drug Administration (FDA) recently announced that it will begin accepting certain forms of de-identified real-world evidence in select medical device applications. The move reflects a growing interest in using data collected outside of traditional clinical trials to support regulatory decision-making.

Real-world evidence can include information gathered from patient registries, electronic health records, claims databases, and other healthcare sources. When appropriately collected and analyzed, these data sets may provide valuable insights into device performance in routine clinical practice.

What This Means for the Medical Device Industry

For medical device manufacturers, this development may create new opportunities to support regulatory submissions and post-market surveillance activities. Real-world evidence has the potential to complement traditional clinical data by providing a broader understanding of how devices perform across diverse patient populations and healthcare settings.

The FDA’s announcement also highlights the increasing importance of data quality, traceability, and robust evidence-generation strategies throughout the product lifecycle.

Why It Matters

As cardiovascular and vascular technologies continue to evolve, access to high-quality clinical and post-market data becomes increasingly important. Regulatory initiatives such as this may help manufacturers better understand device outcomes while supporting informed decision-making throughout the development and commercialization process.

At InSitu Technologies, we closely monitor regulatory developments that may influence medical device innovation, quality systems, and evidence-generation strategies. Staying informed helps us support the evolving needs of healthcare providers, patients, and industry partners.

Source: American Journal of Managed Care (AJMC), June 2026.